BIBLIOGRAPHY

The Use of Systemic Fluoroquinolones in Pediatrics

Susan L. Crecco, PharmD

Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences,
Boston, Massachusetts

J Pediatr Pharmacol Ther 2005;10:104-5

GENERAL

Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. *Drugs* 2002;62:13-59.

Gendrel D, Moulin F. Fluoroquinolones in paediatrics. *Paediatr Drugs* 2001;3:365-77.

Peltola H, Ukkonen P, Saxen H, Stab H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. *Pediatrics* 1998;101:658-62.

Schaad UB, Abdus Salam M, Aujard Y, Dagan R, Green SD, Peltola H, et al. Use of fluoroquinolones in pediatrics: consensus report on an International Society of Chemotherapy commission. *Pediatr Infect Dis J* 1995;14:1-9.

Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, Jacqz-Aigrain E. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. *Antimicrob Agents Chemother* 2003;47:3170-8.

Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. *J Clin Pharmacol* 2003; 43:698-710.

Schaad UB. Pediatric use of quinolones. *Pediatr Infect Dis J* 1999;18:469-70.

SAFETY AND TOXICITY

Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community? *Lancet Infect Dis* 2003;3:537-46.

Chalumeau M, Tonnelier S, D'Athis P, Treluyer JM, Gendrel D, Breart G, Pons G. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. *Pediatrics* 2003;111:e714-9.

Cuzzolin L, Fanos V. Safety of fluoroquinolones in paediatrics. *Expert Opin Drug Saf* 2002;1:319-24.

Yee CL. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. *Pediatr Infect Dis J* 2002;21:525-9.

Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. *Pediatr Infect Dis J* 2002;21:525-29.

Mandell LA, Perterson LR, Wise R, Hooper D, Low DE, Schaad UB, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? *Clin Infect Dis* 2002;35:721-7.

Fanos V, Cuzzolin L. Fluoroquinolones in pediatrics and their nephrotoxicity in adults: minireview. *J Chemother* 2000;12:228-31.

Address correspondence to: Susan L. Crecco, PharmD, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115, e-mail: susan.crecco@bos.mcphs.edu
© 2005 Pediatric Pharmacy Advocacy Group

Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use—safety report. *Pediatr Infect Dis J* 1997;16:127-9.

Burkhart JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. *Clin Infect Dis* 1997;25:1196-1204.

OTITIS MEDIA

Dagan R, Areguedas A, Schaad UB. Potential role of fluoroquinolone therapy in childhood otitis media. *Pediatr Infect Dis J* 2004;23:390-8.

Leibovitz E, Piglansky L, Raiz S, Greenberg D, Hamed KA, Ledezine J, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. *Pediatr Infect Dis J* 2003;22:943-9.

Arguedas A, Sher L, Lopez E, Saez-Llorens X, Hamed K, Skuba K, Pierce PF. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. *Pediatr Infect Dis J* 2003;22:949-55.

Yagupsky P, Katz O, Peled N, Dagan R. In vitro activity of novel fluoroquinolones against *Streptococcus pneumoniae* isolated from children with acute otitis media. *Chemotherapy* 2001;47:354-8.

CYSTIC FIBROSIS

Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. *Pediatr Infect Dis J* 1997;16:572-8.

Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. *Pediatr Infect Dis J* 1997;16:97-105.

Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. *Pediatr Infect Dis J* 1997;16:106-11.

Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. *Antimicrob Agents Chemother* 1996;40:29-34.

Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S, Kubin R. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. *J Int Med Res* 1998;26:304-12.

OTHER INDICATIONS

Saez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. *Pediatr Infect Dis J* 2002;21:14-22.

Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. *Pediatr Infect Dis J* 2000;19:1060-7.

Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. *Pediatr Infect Dis J* 1997;16:118-22.

Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. *Pediatr Infect Dis J* 1997;16:112-7.